The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Discovery of direct inhibitors of Keap1–Nrf2 protein–protein interaction as potential therapeutic and preventive agents
Open accessAbstract
The Keap1-Nrf2-ARE pathway is an important antioxidant defense mechanism that protects cells from oxidative stress and the Keap1-Nrf2 protein-protein interaction (PPI) has become an important drug target to upregulate the expression of ARE-controlled cytoprotective oxidative stress response enzymes in the development of therapeutic and preventive agents for a number of diseases and conditions. However, most known Nrf2 activators/ARE inducers are indirect inhibitors of Keap1-Nrf2 PPI and they are electrophilic species that act by modifying the sulfhydryl groups of Keap1׳s cysteine residues. The electrophilicity of these indirect inhibitors may cause "off-target" side effects by reacting with cysteine residues of other important cellular proteins. Efforts have recently been focused on the development of direct inhibitors of Keap1-Nrf2 PPI. This article reviews these recent research efforts including the development of high throughput screening assays, the discovery of peptide and small molecule direct inhibitors, and the biophysical characterization of the binding of these inhibitors to the target Keap1 Kelch domain protein. These non-covalent direct inhibitors of Keap1-Nrf2 PPI could potentially be developed into effective therapeutic or preventive agents for a variety of diseases and conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nuclear Import and Export Signals in Control of Nrf2
Jain, A. K., Bloom, D. A., & Jaiswal, A. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502083200 · Cited by 195
RetractedPrinciples of Fluorescence Spectroscopy
Lakowicz, J. R. (1999) · Springer eBooks · doi:10.1007/978-1-4757-3061-6 · Cited by 26,947
Principles of Fluorescence Spectroscopy
(2006) · Springer eBooks · doi:10.1007/978-0-387-46312-4 · Cited by 19,339
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725
Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480
Rushmore, T. H., Morton, M. R., & Pickett, C. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99004-6 · Cited by 1,464
The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
Kansanen, E., Kuosmanen, S. M., Leinonen, H., & Levonen, A.-L. (2013) · Redox Biology · doi:10.1016/j.redox.2012.10.001 · Cited by 1,313
Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
Zhang, D. D., Lo, S.-C., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,254
Endogenous DNA damage in humans: a review of quantitative data
De Bont, R. (2004) · Mutagenesis · doi:10.1093/mutage/geh025 · Cited by 1,058
Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
Thimmulappa, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25790 · Cited by 1,028
The cytoprotective role of the Keap1–Nrf2 pathway
Baird, L., & Dinkova-Kostova, A. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0674-5 · Cited by 1,027
Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice
Rangasamy, T., Cho, C. Y., Thimmulappa, R. K., Zhen, L., Srisuma, S. S., Kensler, T. W., Yamamoto, M., Petrache, I., Tuder, R. M., & Biswal, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421146 · Cited by 991
Kobayashi, A., Kang, M.-I., Watai, Y., Tong, K. I., Shibata, T., Uchida, K., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.221-229.2006 · Cited by 933
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 869
Itoh, K., Tong, K. I., & Yamamoto, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.075 · Cited by 864
Small Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
An Important Role of Nrf2-ARE Pathway in the Cellular Defense Mechanism
Lee, J.-M., & Johnson, J. A. (2004) · BMB Reports · doi:10.5483/bmbrep.2004.37.2.139 · Cited by 746
Toward clinical application of the Keap1-Nrf2 pathway
Suzuki, T., Motohashi, H., & Yamamoto, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.005 · Cited by 680
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
McMahon, M. J., Itoh, K., Yamamoto, M. P., Chanas, S. A., Henderson, C. J., McLellan, L. I., Wolf, C. R., Cavin, C., & Hayes, J. D. (2001) · PubMed · Cited by 651
Kobayashi, M., Li, L., Iwamoto, N., Nakajima-Takagi, Y., Kaneko, H., Nakayama, Y., Eguchi, M., Wada, Y., Kumagai, Y., & Yamamoto, M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01080-08 · Cited by 638
Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection
Zhang, M., An, C., Gao, Y., Leak, R. K., Chen, J., & Zhang, F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.09.003 · Cited by 617
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604
When NRF2 Talks, Who's Listening?
Wakabayashi, N., Slocum, S. L., Skoko, J. J., Shin, S., & Kensler, T. W. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3216 · Cited by 595
Direct and indirect antioxidant properties of inducers of cytoprotective proteins
Dinkova-Kostova, A. T., & Talalay, P. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700195 · Cited by 535
Nrf2-Deficient Mice Have an Increased Susceptibility to Dextran Sulfate Sodium–Induced Colitis
Khor, T. O., Huang, M.-T., Kwon, K. H., Chan, J. Y., Reddy, B. S., & Kong, A.-N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3562 · Cited by 530
Antioxidants and human diseases
Rajendran, P., Nandakumar, N., Rengarajan, T., Palaniswami, R., Gnanadhas, E. N., Lakshminarasaiah, U., Gopas, J., & Nishigaki, I. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.06.004 · Cited by 523
Katoh, Y., Itoh, K., Yoshida, E., Miyagishi, M., Fukamizu, A., & Yamamoto, M. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00469.x · Cited by 520
Physiological Significance of Reactive Cysteine Residues of Keap1 in Determining Nrf2 Activity
Yamamoto, T., Suzuki, T., Kobayashi, A., Wakabayashi, J., Maher, J., Motohashi, H., & Yamamoto, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01704-07 · Cited by 513
Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview
Itoh, K., Mimura, J., & Yamamoto, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3222 · Cited by 510
NIOI, P., McMAHON, M., ITOH, K., YAMAMOTO, M., & HAYES, J. D. (2003) · Biochemical Journal · doi:10.1042/bj20030754 · Cited by 507
Oxidative Stress and Neurodegenerative Disorders
Li, J., O, W., Li, W., Jiang, Z.-G., & Ghanbari, H. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224438 · Cited by 504
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601119200 · Cited by 485
Nrf2: friend or foe for chemoprevention?
Kensler, T. W., & Wakabayashi, N. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp231 · Cited by 484
The Nrf2 System as a Potential Target for the Development of Indirect Antioxidants
Jung, K.-A., & Kwak, M.-K. (2010) · Molecules · doi:10.3390/molecules15107266 · Cited by 474
Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism
Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473
Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 442
The Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy
Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., & Zhang, D. D. (2010) · Diabetes · doi:10.2337/db09-1342 · Cited by 440
de Vries, H. E., Witte, M., Hondius, D., Rozemuller, A. J. M., Drukarch, B., Hoozemans, J., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 428
Braun, S., Hanselmann, C., Gassmann, M. G., auf dem Keller, U., Born-Berclaz, C., Chan, K., Kan, Y. W., & Werner, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5492-5505.2002 · Cited by 410
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403061200 · Cited by 404
Nrf2 the rescue: Effects of the antioxidative/electrophilic response on the liver
Klaassen, C. D., & Reisman, S. A. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.01.013 · Cited by 396
NRF2-regulation in brain health and disease: Implication of cerebral inflammation
Sandberg, M., Patil, J., D'Angelo, B., Weber, S. G., & Mallard, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.004 · Cited by 390
Okawa, H., Motohashi, H., Kobayashi, A., Aburatani, H., Kensler, T. W., & Yamamoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.185 · Cited by 387
Protective effect of curcumin against heavy metals-induced liver damage
García-Niño, W. R., & Pedraza-Chaverrí, J. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.04.016 · Cited by 382
The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm
Zipper, L. M., & Mulcahy, R. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206530200 · Cited by 366
Role of oxidatively induced DNA lesions in human pathogenesis
Sedelnikova, O. A., Redon, C. E., Dickey, J. S., Nakamura, A. J., Georgakilas, A. G., & Bonner, W. M. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2009.12.005 · Cited by 336
ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function
Pi, J., Zhang, Q., Fu, J., Woods, C. G., Hou, Y., Corkey, B. E., Collins, S., & Andersen, M. E. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.05.025 · Cited by 334
Sun, Z., Zhang, S., Chan, J. Y., & Zhang, D. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00630-07 · Cited by 332
Zhang, D. D., Lo, S.-C., Sun, Z., Habib, G. M., Lieberman, M. W., & Hannink, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501279200 · Cited by 298
Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases
Gan, L., & Johnson, J. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.011 · Cited by 288
Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease
Aleksunes, L. M., & Manautou, J. E. (2007) · Toxicologic Pathology · doi:10.1080/01926230701311344 · Cited by 285
Katsuoka, F., Motohashi, H., Ishii, T., Aburatani, H., Engel, J. D., & Yamamoto, M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.18.8044-8051.2005 · Cited by 285
Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice
Wruck, C. J., Fragoulis, A., Gurzynski, A., Brandenburg, L.-O., Kan, Y. W., Chan, K., Hassenpflug, J., Freitag-Wolf, S., Varoga, D., Lippross, S., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.132720 · Cited by 283
Bai, Y., Cui, W., Xin, Y., Miao, X., Barati, M. T., Zhang, C., Chen, Q., Tan, Y., Cui, T., Zheng, Y., et al. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.01.008 · Cited by 274
Jiang, Z.-Y., Lu, M.-C., Xu, L., Yang, T.-T., Xi, M.-Y., Xu, X.-L., Guo, X.-K., Zhang, X.-J., You, Q.-D., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 252
Crystal Structure of the Kelch Domain of Human Keap1
Li, X., Zhang, D., Hannink, M., & Beamer, L. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410073200 · Cited by 246
Nrf2, a Guardian of Healthspan and Gatekeeper of Species Longevity
Lewis, K. N., Mele, J., Hayes, J. D., & Buffenstein, R. (2010) · Integrative and Comparative Biology · doi:10.1093/icb/icq034 · Cited by 245
Marcotte, D., Zeng, W., Hus, J.-C., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A., Enyedy, I., Cuervo, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.019 · Cited by 239
Nrf2 protects against airway disorders
Cho, H.-Y., & Kleeberger, S. R. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.024 · Cited by 239
Eggler, A. L., Gay, K. A., & Mesecar, A. D. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700249 · Cited by 235
The Keap1-Nrf2 system and diabetes mellitus
Uruno, A., Yagishita, Y., & Yamamoto, M. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.12.012 · Cited by 231
Mechanism of the Nrf2/Keap1/ARE signaling system
Tkachev, V. O., Menshchikova, E. B., & Zenkov, N. K. (2011) · Biochemistry (Moscow) · doi:10.1134/s0006297911040031 · Cited by 226
NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease
Boutten, A., Goven, D., Artaud-Macari, E., Boczkowski, J., & Bonay, M. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.006 · Cited by 221
Age-Accelerated Atherosclerosis Correlates With Failure to Upregulate Antioxidant Genes
Collins, A. R., Lyon, C. J., Xia, X., Liu, J. Z., Tangirala, R. K., Yin, F., Boyadjian, R., Bikineyeva, A., Praticò, D., Harrison, D. G., et al. (2009) · Circulation Research · doi:10.1161/circresaha.108.188771 · Cited by 215
Katoh, Y., Iida, K., Kang, M.-I., Kobayashi, A., Mizukami, M., Tong, K. I., McMahon, M., Hayes, J. D., Itoh, K., & Yamamoto, M. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.10.012 · Cited by 212
Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis
Stępkowski, T. M., & Kruszewski, M. K. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.033 · Cited by 211
Small molecule modulators of antioxidant response pathway
Hur, W., & Gray, N. S. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.12.009 · Cited by 211
Rachakonda, G., Xiong, Y., Sekhar, K. R., Stamer, S. L., Liebler, D. C., & Freeman, M. L. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700302s · Cited by 207
Yoh, K., Hirayama, A., Ishizaki, K., Yamada, A., Takeuchi, M., Yamagishi, S., Morito, N., Nakano, T., Ojima, M., Shimohata, H., et al. (2008) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01234.x · Cited by 207
Oncogenic functions of the transcription factor Nrf2
Gañán-Gómez, I., Wei, Y., Yang, H., Boyano-Adánez, M. C., & García-Manero, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.041 · Cited by 202
Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction
Hu, L., Magesh, S., Chen, L., Wang, L., Lewis, T. A., Chen, Y., Khodier, C., Inoyama, D., Beamer, L. J., Emge, T. J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.013 · Cited by 200
Self-citationThe Keap1–Nrf2 system as an in vivo sensor for electrophiles
Uruno, A., & Motohashi, H. (2011) · Nitric Oxide · doi:10.1016/j.niox.2011.02.007 · Cited by 188
Huang, X. (2003) · SLAS Discovery · doi:10.1177/1087057102239666 · Cited by 183
Mechanism of Chemical Activation of Nrf2
Li, Y., Paonessa, J. D., & Zhang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035122 · Cited by 179
Oxidative stress in ulcerative colitis: an old concept but a new concern
Jena, G., Trivedi, P. P., & Sandala, B. (2012) · Free Radical Research · doi:10.3109/10715762.2012.717692 · Cited by 177
Binding Mode and Structure–Activity Relationships around Direct Inhibitors of the Nrf2–Keap1 Complex
Jnoff, E., Albrecht, C., Barker, J. J., Barker, O., Beaumont, E., Bromidge, S., Brookfield, F., Brooks, M., Bubert, C., Ceska, T., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300525 · Cited by 176
Eggler, A. L., Small, E., Hannink, M., & Mesecar, A. D. (2009) · Biochemical Journal · doi:10.1042/bj20090471 · Cited by 176
Targeting the Nrf2 pathway against cardiovascular disease
Li, J., Ichikawa, T., Janicki, J. S., & Cui, T. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903025762 · Cited by 171
Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo
Chian, S., Thapa, R., Chi, Z., Wang, X. J., & Tang, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.039 · Cited by 160
Effect of Redox Modulating NRF2 Activators on Chronic Kidney Disease
Choi, B.-H., Kang, K.-S., & Kwak, M.-K. (2014) · Molecules · doi:10.3390/molecules190812727 · Cited by 159
Zhuang, C., Narayanapillai, S. C., Zhang, W., Sham, Y. Y., & Xing, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017174 · Cited by 159
He, X., & Ma, Q. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058453 · Cited by 158
Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction
Hancock, R., Bertrand, H. C., Tsujita, T., Naz, S., El-Bakry, A., Laoruchupong, J., Hayes, J. D., & Wells, G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.486 · Cited by 151
The emerging role of redox-sensitive Nrf2–Keap1 pathway in diabetes
Bhakkiyalakshmi, E., Sireesh, D., Rajaguru, P., Paulmurugan, R., & Ramkumar, K. M. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.10.004 · Cited by 150
Active defense under oxidative stress. The antioxidant responsive element
Lyakhovich, V. V., Андреевич, В. В., Зенков, Н. К., & Брониславовна, М. Е. (2006) · Biochemistry (Moscow) · doi:10.1134/s0006297906090033 · Cited by 123
Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction
Steel, R., Cowan, J., Payerne, E., O'Connell, M. A., & Searcey, M. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300041g · Cited by 113
Deficiency of Nrf2 Accelerates the Effector Phase of Arthritis and Aggravates Joint Disease
Maicas, N., Ferrándiz, M. L., Brines, R., Ibáñez, L., Cuadrado, A., Koenders, M. I., van den Berg, W. B., & Alcaraz, M. J. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3835 · Cited by 112
The absence of macrophage Nrf2 promotes early atherogenesis
Ruotsalainen, A.-K., Inkala, M., Partanen, M. E., Lappalainen, J. P., Kansanen, E., Mäkinen, P. I., Heinonen, S. E., Laitinen, H. M., Heikkilä, J., Vatanen, T., et al. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt008 · Cited by 109
Inoyama, D., Chen, Y., Huang, X., Beamer, L. J., Kong, A. T., & Hu, L. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111430124 · Cited by 105
Self-citationNrf2 and Redox Status in Prediabetic and Diabetic Patients
Jiménez‐Osorio, A. S., Picazo, A., González-Reyes, S., Barrera‐Oviedo, D., Rodríguez-Arellano, M. E., & Pedraza‐Chaverrí, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120290 · Cited by 105
Schaedler, S., Krause, J., Himmelsbach, K., Carvajal-Yepes, M., Lieder, F., Klingel, K., Nassal, M., Weiß, T. S., Werner, S., & Hildt, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145862 · Cited by 104
Smirnova, N. A., Haskew-Layton, R. E., Basso, M., Hushpulian, D. M., Payappilly, J. B., Speer, R. E., Ahn, Y., Rakhman, I., Cole, P. A., Pinto, J. T., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.03.013 · Cited by 96
Hübner, R., Schwartz, J. D., De, B. P., Ferris, B., Omberg, L., Mezey, J. G., Hackett, N. R., & Crystal, R. G. (2009) · Molecular Medicine · doi:10.2119/molmed.2008.00130 · Cited by 93
Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2
Dreger, H., Westphal, K., Wilck, N., Baumann, G., Stangl, V., Stangl, K., & Meiners, S. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp279 · Cited by 92
Hancock, R., Schaap, M., Pfister, H., & Wells, G. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40249e · Cited by 91
Chen, Y., Inoyama, D., Kong, A. T., Beamer, L. J., & Hu, L. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01240.x · Cited by 87
Self-citationThe Antioxidant Response Element and Oxidative Stress Modifiers in Airway Diseases
Reddy, S. P. (2008) · Current Molecular Medicine · doi:10.2174/156652408785160925 · Cited by 83
Regulation of oxidative stress by Nrf2 in the pathophysiology of infectious diseases
Deramaudt, T. B., Dill, C., & Bonay, M. (2013) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2013.02.004 · Cited by 80
Nrf2 is a critical modulator of the innate immune response in a model of uveitis
Nagai, N., Thimmulappa, R. K., Cano, M., Fujihara, M., Izumi‐Nagai, K., Kong, X., Sporn, M. B., Kensler, T. W., Biswal, S. S., & Handa, J. T. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.033 · Cited by 79
Beyer, T. A., auf dem Keller, U., Braun, S., Schäfer, M., & Werner, S. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402133 · Cited by 77
Velmurugan, G. V., Sundaresan, N. R., Gupta, M. P., & White, C. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt125 · Cited by 76
Nrf2: bane or blessing in cancer?
Xiang, M., Namani, A., Wu, S., & Wang, X. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1627-1 · Cited by 71
Córdova, E., Velázquez‐Cruz, R., Centeno-Cruz, F., Baca, V., & Orozco, L. (2010) · Lupus · doi:10.1177/0961203310367917 · Cited by 70
Stachel, I., Geismann, C., Aden, K., Deisinger, F., Rosenstiel, P. C., Schreiber, S., Sebens, S., Arlt, A., & Schäfer, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490920 · Cited by 62
Sun, H.-P., Jiang, Z., Zhang, M.-Y., Lu, M., Yang, T., Pan, Y., Huang, H., Zhang, X., & You, Q. (2013) · MedChemComm · doi:10.1039/c3md00240c · Cited by 59
Experimental Therapeutics of Nrf2 as a Target for Prevention of Bacterial Exacerbations in COPD
Biswal, S. S., Thimmulappa, R. K., & Harvey, C. J. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-009ms · Cited by 47
Conserved solvent and side-chain interactions in the 1.35 Å structure of the Kelch domain of Keap1
Beamer, L. J., Li, X., Bottoms, C. A., & Hannink, M. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905022626 · Cited by 42
Nuclear factor erythroid 2-like 2 (Nrf2) expression in end-stage liver disease
Kurzawski, M., Dziedziejko, V., Urasińska, E., Post, M., Wójcicki, M., Miętkiewski, J., & Droździk, M. (2012) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2012.03.001 · Cited by 32
Chauhan, N., Chaunsali, L., Deshmukh, P. H., & Padmanabhan, B. (2013) · Bioinformation · doi:10.6026/97320630009450 · Cited by 29
Nrf2 protects against furosemide-induced hepatotoxicity
Qu, Q., Liu, J., Zhou, H., & Klaassen, C. D. (2014) · Toxicology · doi:10.1016/j.tox.2014.02.008 · Cited by 25
Cited by
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Lu, M., Ji, J., Jiang, Z., & You, Q. (2016) · Medicinal Research Reviews · doi:10.1002/med.21396 · Cited by 790
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
Progress in the mechanism and targeted drug therapy for COPD
Wang, C., Zhou, J., Wang, J., Li, S., Fukunaga, A., Yodoi, J., & Tian, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00345-x · Cited by 303
Krajka-Kuźniak, V., Paluszczak, J., & Baer-Dubowska, W. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2016.12.011 · Cited by 288
Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke
Hikichi, M., Mizumura, K., Maruoka, S., & Gon, Y. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.10.43 · Cited by 283
Metadata
- Authors
- Abed, D. A., Goldstein, M., Albanyan, H., Jin, H., & Hu, L.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 5
- Issue
- 4
- Pages
- 285-299
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W840875033
- Cited by
- 319
- References
- 119
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.